Der er i kliniske forsøg med type 1 diabetes patienter vist en lavere risiko for natlig hypoglykæmi med insulin aspart end med opløseligt humant insulin.
Clinical trials in patients with type 1 diabetes have demonstrated a reduced risk of nocturnal hypoglycaemia with insulin aspart compared with soluble human insulin.